Showing results (1931-1940 of 2,286) with videos related to
Sort By:
Pageof 229
The Journal of Clinical Investigation|March 21, 2024
Dietary carbohydrates regulate intestinal colonization and dissemination of Klebsiella pneumoniaeAaron L Hecht, Lisa C Harling, Elliot S Friedman, et al.Investigative Ophthalmology & Visual Science|April 28, 2021
IMI Impact of MyopiaPadmaja Sankaridurg, Nina Tahhan, Himal Kandel, et al.Cancer Research|November 16, 2011
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibitionKlaus P Hoeflich, Mark Merchant, Christine Orr, et al.Science (New York, N.Y.)|August 9, 2008
Deletional tolerance mediated by extrathymic Aire-expressing cellsJames M Gardner, Jason J Devoss, Rachel S Friedman, et al.Investigative Ophthalmology & Visual Science|December 17, 2008
Prevalence and associations of epiretinal membranes in a rural Chinese adult population: the Handan Eye StudyXin Rong Duan, Yuan Bo Liang, David S Friedman, et al.Nuclear Medicine and Biology|May 15, 2007
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspectsRoger E McLendon, Gamal Akabani, Henry S Friedman, et al.Journal of Clinical Pharmacology|April 29, 2026
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl EstradiolCarol Cronenberger, Neeta B Amin, Vu H Le, et al.Neuro-Oncology Practice|August 15, 2025
Phase II randomized glioma study to evaluate efficacy and satisfaction of rolapitant plus ondansetron in preventing chemoradiation-induced nausea and vomitingMary Lou Affronti, Mallika P Patel, Erin K Severance, et al.Ocular Immunology and Inflammation|July 21, 2011
Morphologic assessment for glaucoma in the Multicenter Uveitis Steroid Treatment (MUST) trialSapna S Gangaputra, Michael M Altaweel, Qian Peng, et al.Cancer|May 19, 2011
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyDavid A Reardon, Annick Desjardins, Katherine B Peters, et al.Pageof 229